New paradigms in the treatment of hepatic cholestasis: From UDCA to FXR, PXR and beyond
Top Cited Papers
Open Access
- 1 April 2015
- journal article
- review article
- Published by Elsevier BV in Journal of Hepatology
- Vol. 62 (1), S25-S37
- https://doi.org/10.1016/j.jhep.2015.02.023
Abstract
No abstract availableKeywords
This publication has 100 references indexed in Scilit:
- Differential effects of norUDCA and UDCA in obstructive cholestasis in miceJournal of Hepatology, 2013
- TGR5 Activation Inhibits Atherosclerosis by Reducing Macrophage Inflammation and Lipid LoadingCell Metabolism, 2011
- The G-Protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor kappa light-chain enhancer of activated B cells (NF-κB) in miceJournal of Hepatology, 2011
- FGF15/19 Regulates Hepatic Glucose Metabolism by Inhibiting the CREB-PGC-1α PathwayCell Metabolism, 2011
- Regulation of multidrug resistance-associated protein 2 by calcium signaling in mouse liverJournal of Hepatology, 2010
- Hypertrophic cardiomyopathy and dysregulation of cardiac energetics in a mouse model of biliary fibrosisJournal of Hepatology, 2010
- High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitisJournal of Hepatology, 2009
- Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2−/− miceJournal of Hepatology, 2009
- Endocrine Regulation of the Fasting Response by PPARα-Mediated Induction of Fibroblast Growth Factor 21Cell Metabolism, 2007
- Drug Insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasisNature Clinical Practice Gastroenterology & Hepatology, 2006